This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Immune-mediated myopathies with antibodies may be triggered by statin exposure, but some patients with these disorders are statin-naive; thus, there are probably other etiologies.1 Several malignant tumors, including esophageal squamous cell carcinoma (ESCC), overexpress 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) protein.2 To date, the relationship between anti-HMGCR antibody–associated myopathy (HMGCR-M) and malignancy remains unclear.3,4 Here, we report a case of HMGCR-M in a patient with ESCC and paraneoplastic syndrome.
Footnotes
Supplemental data at Neurology.org
Author contributions: K.T.: study design and concept, data acquisition, analysis and interpretation, drafting the manuscript. K.H.: analysis and interpretation, data acquisition. Y.M.: analysis and interpretation, data acquisition, critical manuscript revision. H.N.: analysis and interpretation, data acquisition. Y.N.: analysis and interpretation, data acquisition. M. Koike: analysis and interpretation, data acquisition. S.N.: analysis and interpretation, data acquisition. Y.R.: analysis and interpretation, data acquisition. K.S.: analysis and interpretation, data acquisition, manuscript revisions. N.A.: analysis and interpretation, data acquisition, manuscript revision. M.I.: analysis and interpretation, data acquisition. Y.S.: analysis and interpretation, data acquisition. M.A.: analysis and interpretation, data acquisition. M. Katsuno: study supervision, critical manuscript revisions, data interpretation, study design and concept.
Study funding: Supported by KAKENHI grants from MEXT/JSPS, Japan (no. 26293206, 15K15337).
Disclosure: K. Tsujikawa reports no disclosures relevant to the manuscript. K. Hara is supported by KAKENHI Grant-in-Aid for Young Scientists B from JSPS, Japan (No. 15K1984). Y. Muro serves as an editorial board member of Immunopharmacology and Immunotoxicology and the Open Rheumatology Journal. He is supported by KAKENHI Grant-in-Aid for Scientific Research C from JSPS, Japan (No. 26461656). H. Nakanishi reports no disclosures relevant to the manuscript. Y. Niwa is supported by KAKENHI Grant-in-Aid for Young Scientists B from JSPS, Japan (No. 15K19878). M. Koike and S. Noda report no disclosures relevant to the manuscript. Y. Riku is supported by KAKENHI Grant-in-Aid for Young Scientists B from JSPS, Japan (No. 15K19483) and a grant from the Nitto Foundation. K. Sahashi is supported by KAKENHI Grant-in-Aid for Scientific Research C from JSPS, Japan (No. 26461268). N. Atsuta is supported by KAKENHI Grant-in-Aid for Scientific Research C from JSPS, Japan (No. 25461277). M. Ito is supported by KAKENHI Grant-in-Aid for Scientific Research C from JSPS, Japan (No. 25461313). Y. Shimoyama reports no disclosures relevant to the manuscript. M. Akiyama serves as a section editor of Journal of Dermatological Science and the Journal of Dermatology. He is supported by KAKENHI Grant-in-Aid for Scientific Research B from JSPS, Japan (No. 15H04887). M. Katsuno is supported by KAKENHI grants from JSPS, Japan (No. 26293206, 15K15337); a grant from Japan Agency for Medical Research and Development (No. 15ek0109025); and a grant from the Daiichi Sankyo Foundation of Life Science. Go to Neurology.org for full disclosures.
- Received December 26, 2015.
- Accepted in final form May 9, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg